IXICO PLC announced a 23% increase in revenues and a 38% growth in its order book, driven by strong demand in Alzheimer’s disease clinical trials and new contracts in diagnostics. CEO Bram Goorden highlighted the company’s TechBio strategy, supported by a recent £10 million capital raise, aimed at productizing their IXI technology platform to enhance automation and scalability. The company is expanding geographically, especially in the US and Asia, while maintaining momentum in its imaging CRO business. With 95% of 2026 revenues secured, IXICO expects continued growth focused on neurodegenerative diseases and technology-driven recurring revenues.
Uber Technologies Inc. has made a full takeover offer for Delivery Hero at €33 per share, slightly below Delivery Hero's recent closing price. Prior to the offer, Uber increased its stake in Delivery Hero from about 7% to 19.5%, becoming the largest ...
Uniswap (UNI) is under selling pressure, with its price down 7.5% to $3.44 and trading volume up 61%, signaling strong market activity. Negative derivatives data and a falling Long/Short ratio indicate traders expect further declines, possibly to the...
U.S.-based spot Bitcoin ETFs experienced significant outflows totaling $1.2 billion over five days, marking the third worst week on record for these funds. The largest single-day withdrawal was $647 million on May 18, followed by continued losses thr...
XRP is trading in a tight range between $1.33 and $1.49, showing a bearish consolidation with weak momentum as it stays below its 200-day moving average. AI models indicate that while sellers currently control the market, repeated support at $1.33 su...
This article highlights eight companies that are progressing steadily toward achieving Dividend King status, which requires at least 50 consecutive years of dividend increases. Although these companies are not expected to reach this milestone until 2...
